 |
|
Newly Discovered Gene Fusion May Lead to Improved Prostate Cancer Diagnosis
July 24, 2009NewYork-Presbyterian/Weill Cornell Team Finds Protein Produced by Gene Fusion That May Also Be Targeted for New Therapies
NEW YORK - Researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered a new gene fusion that is highly expressed in a subset of prostate cancers. The results may lead to more accurate prostate cancer testing and new targets for potential treatments. Experts believe that gene fusions - a hybrid gene formed from two previously separated genes - may be at the root of what causes cancer cells to grow more quickly than normal cells.
The new findings, published in the August issue of the journal Neoplasia, are exciting, because unlike two previous fusions co-discovered by the same Weill Cornell Medical College laboratory group, this fusion, called NDRG1-ERG, produces a protein that may be a potential target for drug therapies.
"The prostate cancer gene fusions, and proteins they produce, are important because they serve as a cancer-specific marker," says Dr. Mark A. Rubin, the Homer T. Hirst Professor of Oncology in Pathology, professor of pathology and laboratory medicine, and vice chair for experimental pathology at Weill Cornell Medical College. "Currently, PSA testing is the standard of care, yet it is not accurate enough to predict prostate cancer, because many men may have an elevated PSA level, but have benign conditions such as inflammation of the prostate."
It is important to distinguish harmful cancer from non-lethal diseases, such as benign prostatic hyperplasia, or enlarged prostate disease that exhibits similar symptoms to prostate cancer, in order to provide effective care, explains Dr. Rubin. Gen-Probe, a biotechnology diagnostics company, has licensed this technology and is currently working with Dr. Rubin, and his collaborator Dr. Arul Chinnaiyan at the University of Michigan, to develop urine tests to screen for gene fusions as a means of improving upon the current standard PSA test.
Dr. Rubin, working in collaboration with Dr. Chinnaiyan's group at the University of Michigan, previously described the discovery of the TMPRSS2-ERG fusion found in 45 percent of prostate cancers. The new gene fusion, although only seen in 5 percent of prostate cancers, is the only one of this fusion class that is predicted to produce a protein.
This fusion protein may be a target for drug therapy and could help target the other more common gene fusions.
"In the future, these fusions, specific to certain types of prostate cancer, may help physicians prescribe tailored therapies for their patients by avoiding the trial and error that is often associated with cancer treatments," says Dr. Rubin, who is also the associate director of translational research and a pathologist at the Weill Cornell Cancer Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
"We believe this is a first step toward providing patients with specific therapies that target individual cancer variants, and hope these findings will help doctors diagnose a patient's specific disease," explains Dr. Rubin.
Novel Gene Fusion Sheds Light on How Cancer Works
Unlike most of the gene fusions previously found in prostate cancer, the two genes, NDRG1 and ERG, likely produce a cancer-specific protein through genetic rearrangements. This fusion and protein are only found in cancer cells, and not within normal cells. Ongoing work is exploring the potential biologic implications of this discovery. However, the diagnostic implications are more immediate because these types of genetic chimera occur only in cancer.
"We think this type of gene fusion might be a common mechanism in other cancers," Dr. Rubin says. "This expands our understanding of how prostate tumor cells can hijack androgen-regulated genes by using neighboring genes to effectively alter their regulation. This may be a way tumors gain a competitive advantage over normal tissue."
Novel Technology Employed to Make Discovery
Dr. Rubin's team used state-of-the-art gene sequencing tools to discover the new class of gene fusion. Using pair-end digital sequencing of messenger RNA - the message that all cells produce - the computational team, lead by Dr. Mark Gerstein from Yale University and Andrea Sboner from Weill Cornell Medical College, were able to identify messages that emanated from two separate genes. The approach led to the discovery of the new gene fusion. The team is actively working on identifying other novel fusions with this approach, which will be applicable to other tumors as well.
Additional co-authors include Dorothee Pflueger, Dr. David S. Rickman, Andrea Sboner, Christopher LaFargue, Maria Svensson, Benjamin Moss, Naoki Kitabayashi, Dr. Yihang Pan, Dr. Ashutosh K. Tewari and Dr. Francesca Demichelis from Weill Cornell Medical College; Dr. Alexandre de la Taille from the CHU Mondor (Créteil, France); and Dr. Rainer Kuefer and Dr. Mark Chee from Ulm University Hospital (Ulm, Germany).
Weill Cornell Medical College
"The prostate cancer gene fusions, and proteins they produce, are important because they serve as a cancer-specific marker," says Dr. Mark A. Rubin, the Homer T. Hirst Professor of Oncology in Pathology, professor of pathology and laboratory medicine, and vice chair for experimental pathology at Weill Cornell Medical College. "Currently, PSA testing is the standard of care, yet it is not accurate enough to predict prostate cancer, because many men may have an elevated PSA level, but have benign conditions such as inflammation of the prostate."
It is important to distinguish harmful cancer from non-lethal diseases, such as benign prostatic hyperplasia, or enlarged prostate disease that exhibits similar symptoms to prostate cancer, in order to provide effective care, explains Dr. Rubin. Gen-Probe, a biotechnology diagnostics company, has licensed this technology and is currently working with Dr. Rubin, and his collaborator Dr. Arul Chinnaiyan at the University of Michigan, to develop urine tests to screen for gene fusions as a means of improving upon the current standard PSA test.
Dr. Rubin, working in collaboration with Dr. Chinnaiyan's group at the University of Michigan, previously described the discovery of the TMPRSS2-ERG fusion found in 45 percent of prostate cancers. The new gene fusion, although only seen in 5 percent of prostate cancers, is the only one of this fusion class that is predicted to produce a protein.
This fusion protein may be a target for drug therapy and could help target the other more common gene fusions.
"In the future, these fusions, specific to certain types of prostate cancer, may help physicians prescribe tailored therapies for their patients by avoiding the trial and error that is often associated with cancer treatments," says Dr. Rubin, who is also the associate director of translational research and a pathologist at the Weill Cornell Cancer Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
"We believe this is a first step toward providing patients with specific therapies that target individual cancer variants, and hope these findings will help doctors diagnose a patient's specific disease," explains Dr. Rubin.
Novel Gene Fusion Sheds Light on How Cancer Works
Unlike most of the gene fusions previously found in prostate cancer, the two genes, NDRG1 and ERG, likely produce a cancer-specific protein through genetic rearrangements. This fusion and protein are only found in cancer cells, and not within normal cells. Ongoing work is exploring the potential biologic implications of this discovery. However, the diagnostic implications are more immediate because these types of genetic chimera occur only in cancer.
"We think this type of gene fusion might be a common mechanism in other cancers," Dr. Rubin says. "This expands our understanding of how prostate tumor cells can hijack androgen-regulated genes by using neighboring genes to effectively alter their regulation. This may be a way tumors gain a competitive advantage over normal tissue."
Novel Technology Employed to Make Discovery
Dr. Rubin's team used state-of-the-art gene sequencing tools to discover the new class of gene fusion. Using pair-end digital sequencing of messenger RNA - the message that all cells produce - the computational team, lead by Dr. Mark Gerstein from Yale University and Andrea Sboner from Weill Cornell Medical College, were able to identify messages that emanated from two separate genes. The approach led to the discovery of the new gene fusion. The team is actively working on identifying other novel fusions with this approach, which will be applicable to other tumors as well.
Additional co-authors include Dorothee Pflueger, Dr. David S. Rickman, Andrea Sboner, Christopher LaFargue, Maria Svensson, Benjamin Moss, Naoki Kitabayashi, Dr. Yihang Pan, Dr. Ashutosh K. Tewari and Dr. Francesca Demichelis from Weill Cornell Medical College; Dr. Alexandre de la Taille from the CHU Mondor (Créteil, France); and Dr. Rainer Kuefer and Dr. Mark Chee from Ulm University Hospital (Ulm, Germany).
Weill Cornell Medical College
Gene Fusion Current Events and Gene Fusion News RSSScripps Research scientists find early evolution maximized the 'spellchecking' of protein sequences
As letters of the alphabet spell out words, when amino acids are linked to one another in a particular order they "spell out" proteins.
Genetic marker may predict early onset of prostate cancer
Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer.
Gene fusion discovery may lead to improved prostate cancer test
A newly discovered gene fusion is highly expressed in a subset of prostate cancers, according to a study by researchers at Weill Cornell Medical College.
Estrogen Helps Drive Distinct, Aggressive Form of Prostate Cancer
Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.
Genes offer researchers a 'crystal ball' to help them prevent, diagnose and treat cancer
The science of cancer prevention has advanced to the point where researchers now say they can detect "cancer genes" in the breath of smokers, and can test the presence of two proteins in men they say will predict development of prostate cancer a decade in advance.
Novel protein complex enables survival in hostile environment
Biswarup Mukhopadhyay and Eric Johnson from the Virginia Bioinformatics Institute at Virginia Tech have discovered a novel enzyme that represents an ancient detoxification system and provides a clue to the development of early metabolism on earth.
More Gene Fusion Current Events and Gene Fusion News Articles
 |
I Still Believe Gene Dunlap (Primary Contributor) |
 |
Ballad Essentials by Gene Harris |
|
Experiments With Gene Fusions by Thomas J. Silhavy (Author), Michael L. Berman (Author), L. W. Enquist (Author) | |
 |
Gene Pool Gene Ess (Primary Contributor) |
 |
Take Your Time Blue" Gene Tyranny (Composer), "Blue" Gene Tyranny (Composer) A CD of works for solo piano. "Thirty-five of the 36 songs in this 'audio storyboard' are individually built around an atmospheric primary chord, counter-rhythms, and a body of notes which creates a potential melody that unfolds bit by bit. 'The Driver's Son' is scored for a narrator, a chorus of 5 people creating 15 voices, an electronically modified orchestra of folk and concert instruments and parts for a lighting designer and a live video animator known as The Guide. The realization for electro-magnetically stimulated piano (1993) heard here employs feedback circuit devices, designed by composer David Meschter, that initiate subtle sustaining tones when placed on the strings. The slowly appearing, ethereal sounds in this piece are 'artificial harmonics' that resonate high in the piano... |
 |
Intro Gene Krupa 2 Gene Krupa (Primary Contributor) |
|
Insight into gene fusion from molecular dynamics simulation of fused and un-fused IGPS (Imidazole Glycerol Phosphate Synthetase).(Hypothesis): An article from: Bioinformation by Yu Yiting (Author), Li Lei (Author), Meena Kishore Sakharkar (Author), Pandjassarame Kangueane (Author) This digital document is an article from Bioinformation, published by Thomson Gale on January 1, 2006. The length of the article is 2979 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Insight into gene fusion from molecular dynamics simulation of fused and un-fused IGPS (Imidazole Glycerol Phosphate Synthetase).(Hypothesis) Author: Yu Yiting Publication: Bioinformation (Magazine/Journal) Date: January 1, 2006 Publisher: Thomson Gale Page: 99(6) Distributed by Thomson... | |
|
|
Intro Gene Krupa Gene Krupa (Primary Contributor) |
 |
This Same Temple Paul Dresher (Composer), Gene Reffkin (Composer), Sarah Willner (Composer), Nurit Tilles (Composer), Edward Neimann (Composer) The works on this CD are all from what Dresher considers to be his first phase of composition in his own musical voice, ranging from 1976 through 1985. They focus entirely on the three instruments he knew best and has worked with since childhood: the guitar, the piano and the tape recorder. Liquid and Stellar Music began as an idea for a sonic world while working with Terry Riley at Mills College and was working exclusively with the electric guitar. Through the use of a four-channel tape machine with three playback heads located at various points in the path of a closed loop of variable speed, system, it is possible for the performer to build up complex textural, harmonic or rhythmic structures through what is essentially a process of live multi-track recording (and playback, erasing... |
|
Cell Fusion: Gene Transfer and Transformation (Miles International Symposium Series) by Roland F. Beers (Editor) |
| © 2009 BrightSurf.com |